News

We are thrilled that our Clinical Research Coordinator Alexandra Lenart has been accepted to medical school at Michigan State University College of Osteopathic Medicine. She is grateful for her time in the lab and the entire team!

We're excited to announce that PETAL's latest manuscript, "Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma" has been published in Expert Opinion On Pharmacotherapy.

We're proud to announce that our latest manuscript, "Allogeneic Transplant Outcomes in T-Cell Prolymphocytic Leukemia: A single-center retrospective study," has been published in Leukemia and Lymphoma.

We're excited to announce that PETAL's latest manuscript, "Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium" has been published in Leukemia and Lymphoma.

Congratulations to Dr. Makoto Iwasaki, Co-investigator at PETAL Consortium, on being selected as a 2026 Lymphoma Research Foundation Scholar in the Lymphoma Scientific Research Mentoring Program (LSRMP). The LSRMP is a mentoring program from the Lymphoma Research Foundation (LRF). The program provides education for those pursuing lymphoma research, including training in research methods and design, statistical analysis, pathology, incorporating and interpreting correlative studies into clinical trials, and grant submission. Dr. Iwasaki is grateful for the LRF’s support of his research.

Global study finds early relapse predicts poor outcomes in patients with aggressive blood cancer

A new study led by investigators from PETAL Consortium at the Mass General Brigham Cancer Institute found that among patients who achieved a complete remission after initial chemotherapy treatment, survival was worse for those whose disease relapsed within 12 months of initial treatment, suggesting that alternative strategies are needed to benefit these patients.

Research Spotlight: Early Relapse Predicts Poor Outcomes in Aggressive Blood Cancer

In this research spotlight, learn about a global study led by Mark Sorial that examined patients with mature nodal T-cell lymphoma—a rare and aggressive blood cancer. The study found that patients whose cancer returns within 12 months have poorer survival outcomes but may benefit from earlier use of non-chemotherapy treatments. He explains how these findings help clarify differences in patient outcomes and pave the way for more personalized treatment strategies.

PETAL Consortium’s fourth manuscript accepted by Blood!

We’re thrilled to announce that PETAL’s fourth manuscript, “Early time-to-relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium,” has been accepted for publication in Blood–the world’s leading and most widely cited journal in hematology. The paper is scheduled for publication in early December!

Dr. Salvia Jain interviewed by Becker's Healthcare
Salvia Jain, MD, principal investigator and founder of PETAL Consortium, spoke with Becker's Healthcare about how combining the drugs duvelisib and romidepsin may offer a promising path to stem cell transplant for patients with peripheral and cutaneous T-cell lymphomas.

In this Q&A, meet Caroline MacVicar, former Clinical Research Coordinator for PETAL Consortium.


Caroline is an incoming first year medical student in the Army at Uniformed Services University and former Clinical Research Coordinator in the Jain Lab. She earned her bachelor's degree in Biological Sciences from Wellesley College. She was a volunteer at the Newton-Wellesley Hospital and was an undergraduate research assistant in a microbiology lab at Wellesley.

In this Q&A, meet Mark Sorial, PETAL Consortium’s Investigator and Biostatistician!

Mark Sorial is an Investigator and Biostatistician at Massachusetts General Hospital. He earned his Doctor of Pharmacy degree at the Massachusetts College of Pharmacy and Health Sciences and is now completing his Masters of Public Health at the University of Massachusetts Amherst. He is currently a Clinical Pharmacist Specialist at the Dana-Farber Cancer Institute.

Research Spotlight: Global Study Finds Improved Survival for Aggressive Blood Cancer with Early Use of Existing Drug Therapies

In this research spotlight, learn about Mark Sorial's recent publication on improved survival for patients with lymphoma with the use of existing drug therapies. He shares how these discoveries can improve patient care and lead to better treatment strategies.

Research Spotlight: Study Demonstrates Drug Combination is Well-Tolerated, Safe and Effective for Patients with Aggressive Blood Cancer
In this research spotlight, learn about Josie Ford's recent publication on a novel drug combination for lymphoma. She shares how the team's findings could shape future approaches to care for patients with aggressive blood cancers.

In this QSA, meet Alexandra Lenart, PETAL
Consortium's CRC!
Alexandra Lenart is a Clinical Research Coordinator (CRC) at Massachusetts General Hospital. She earned her bachelor's degree in Economics at Wellesley College. Before joining PETAL Consortium, she was a Scrub Technician at Oral and Maxillofacial Surgery of Central New Jersey, as well as a Research Assistant in the Tetel Lab at Wellesley College.

Founder and Principal investigator of the PETAL Consortium

In this Q&A, meet Dr. Salvia Jain–founder and principal investigator of PETAL Consortium–as she shares how her journey in medicine began and what inspired her to focus on blood cancer research.

We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending dimedical school at Uniformed Services University (USU).Congratulations!

Is There a Role for MRD in Predicting Outcome Post Transplant? Presented by Dr. Salvia Jain.

PETAL Consortium: Transforming the Tc-Cell Lymphoma Research Landscape Presented by Forum Bhanushali

Integrative Analysis of Histone Modifications and 3D Chromatin Organization Reveals Altered Epigenetic Landscapes across T-Cell Lymphoma Subtypes Presented by Caroline MacVicar